EVO · Evotec
AI read · Good for EVO
The AI's read
This adds a second candidate to the partnership's early drug development work. The first candidate entered a Phase 1 trial in March 2026, and this one is expected to begin a Phase 1 trial in 2027. These steps show progress, but neither proves the drugs will work in patients.
BMY · Bristol Myers Squibb
AI read · Good for BMY
The connection
Bristol Myers Squibb's partnership with Evotec reached a second FDA-accepted candidate, after the first entered a Phase 1 trial in March 2026. The new candidate is not expected in a Phase 1 trial until 2027, so this is progress, not proof of a working drug.